NewsBenzingaCullinan Therapeutics ottiene l’autorizzazione della FDA e dell’Australian Therapeutic Goods Administration per avviare il suo studio clinico globale di fase 1b/2a negli adulti con ITP recidivante e refrattaria e anemia emolitica autoimmune calda Cullinan Therapeutics ottiene l’autorizzazione della FDA e dell’Australian Therapeutic Goods Administration per avviare il suo studio clinico globale di fase 1b/2a negli adulti con ITP recidivante e refrattaria e anemia emolitica autoimmune calda Benzinga 2026.10.27 11:09 (GMT+0) Open on Benzinga Other news Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says How to Play NKE Stock as Nike Risks Becoming a Forever Turnaround Story